Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What is Genetic Engineering?00:49

What is Genetic Engineering?

81.4K
Overview
81.4K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

86
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.6K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

112
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112
Transgenic Organisms00:53

Transgenic Organisms

6.3K
6.3K
Transgenic Organisms00:53

Transgenic Organisms

34.4K
Overview
34.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adipose Tissue Memory and Why Patients Regain Weight after Weight Loss: Understanding the Immunologic Basis for Recurrent Cardiovascular Risk.

Cardiology in review·2026
Same author

Nonocclusive Mesenteric Ischemia in Cardiogenic Shock: Mechanisms of Splanchnic Hypoperfusion and Strategies for Early Detection.

Cardiology in review·2026
Same author

Risk stratification for sudden cardiac death in nonischemic dilated cardiomyopathy: a moving target?

Frontiers in cardiovascular medicine·2026
Same author

E-cigarette/vaping associated lung injury: an ongoing public health crisis.

BMJ case reports·2026
Same author

Understanding Dysfunctional Autophagy and Mitophagy in Inflammatory Cardiovascular Disease.

Cardiology in review·2026
Same author

The Cardiopulmonary Complications of Vaping.

Cardiology in review·2026
Same journal

Beta-Blockers Versus Flecainide for Atrial Fibrillation: A First-Line Strategy Review of Efficacy, Safety, and Patient Selection.

Cardiology in review·2026
Same journal

Cerebrovascular Disease in Pregnancy: Epidemiology, Pathophysiology, Risk Factors, Diagnostic and Management Considerations, Long-Term Maternal Outcomes: A Narrative Review.

Cardiology in review·2026
Same journal

Immunometabolism in Cardiovascular Disease: Linking Metabolic Reprogramming to Inflammation, Atherothrombosis, and Clinical Outcomes.

Cardiology in review·2026
Same journal

Cardiotoxicity of Antibody-Drug Conjugates in HER2-Positive Cancer: Beyond Left Ventricular Ejection Fraction Decline.

Cardiology in review·2026
Same journal

Celiac Disease and Cardiovascular Disease: Epidemiology, Mechanisms, and Clinical Challenges.

Cardiology in review·2026
Same journal

Valve-Specific Comparative Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists After Surgical Valve Procedures in Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Cardiology in review·2026
See all related articles

Related Experiment Video

Updated: Apr 3, 2026

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.1K

Genetically Modified Foods: Have They Reduced Cardiovascular Risk?

Michael E Kaiser1, Brenna M Farmer2,3, Manish A Parikh1,4

  • 1From the Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY.

Cardiology in Review
|April 2, 2026
PubMed
Summary
This summary is machine-generated.

Genetically modified organism (GMO) foods are as safe as conventional foods. Nutritional biofortification in GMOs can improve cardiovascular health by balancing fatty acids, but overall diet quality remains key for reducing disease risk.

Keywords:
alpha linoleic acidbiofortification, linoleic acidcardiovascular diseasegenetic engineeringgenetically modified organism foodsgenetically modified organismsheart disease riskomega-6/omega-3 ratiopolyunsaturated fatty acids

More Related Videos

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.9K
Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

2.2K

Related Experiment Videos

Last Updated: Apr 3, 2026

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.1K
Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.9K
Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

2.2K

Area of Science:

  • Nutritional Science
  • Biotechnology
  • Cardiovascular Health

Background:

  • Cardiovascular disease (CVD) is a leading cause of death globally.
  • Genetically modified organisms (GMOs) are debated for their health impacts, particularly concerning CVD.
  • Nutritional engineering aims to enhance food composition, focusing on polyunsaturated fatty acids to address omega-6/omega-3 imbalances.

Purpose of the Study:

  • To evaluate the positive and adverse associations of GMO consumption on human health, specifically cardiovascular disease.
  • To provide a balanced perspective on the safety and benefits of GMOs in relation to CVD.
  • To assess the role of nutritional biofortification and plant-based diets in managing CVD risk.

Main Methods:

  • Literature review evaluating GMO safety, plant-based diets, biofortified crops, and omega-6/omega-3 ratios.
  • Analysis of studies examining associations between GMO consumption and health outcomes, including CVD.
  • Assessment of nutritional engineering strategies for improving food composition and their impact on cardiovascular health.

Main Results:

  • Regulatory bodies consider GMO foods as safe as conventional counterparts.
  • Nutritional biofortification can enhance omega-3 fatty acid content, potentially reducing inflammation and improving lipid profiles.
  • Plant-based diets with enhanced crops show lower CVD incidence and mortality.
  • GMOs do not increase CVD risk unless part of ultraprocessed foods; the overall diet is the primary determinant of risk.

Conclusions:

  • GMO foods are deemed safe by regulatory agencies.
  • Nutritional biofortification of crops offers a promising strategy to improve cardiovascular health by optimizing fatty acid profiles.
  • The overall dietary pattern, rather than GMOs themselves, is the critical factor in managing and reducing cardiovascular disease risk.